Hematology

Delayed anemia treatment with ESAs was not correlated with worse renal events but elevated the risk of cardiovascular events and all-cause mortality.

Anemia is common in high-risk PCI and is independently associated with major adverse cardiovascular events and major bleeding risk.

Our July 2024 hematology month in review examines the latest updates to the hematological pipeline and key study data informing clinical practice.

Patients with hemoglobin SS sickle cell disease type may experience a significantly elevated risk of retinal vascular occlusion.

Patient factors trended towards an association with a higher risk of proliferative sickle cell retinopathy but did not reach statistical significance.

Giroctocogene fitelparvovec achieved primary and key secondary objectives of superiority compared to routine prophylaxis in hemophilia A treatment.

A study found individuals with type 2 diabetes who received less than 7 hours of sleep had 2.6 increased odds of microvascular disease.

The XTEND-Kids phase 3 trial shows efanesoctocog alfa’s safety and efficacy in children with severe hemophilia A, reducing bleeds with once-weekly dosing.

A study from the ASH Research Network reports positive antibody response and tolerability after mRNA vaccination in people with sickle cell disease.

Interim analysis of the Phase 2 study shows an overall response rate of 40% in patients aged 2 years to younger than 18 years with chronic GVHD.

Most patients administered IV iron after acute bacterial infection did not experience negative clinical outcomes.

Online survey data underlines notable discrepancies across various aspects of ID screening and supplementation in clinical practice for patients with HF.

Iron deficiency and anemia rates were typically higher in less economically developed regions and rural areas in China.

Long-term exposure to proton pump inhibitors and oral anticoagulants was linked to an increased risk of IDA presentation.

Patients with chronic kidney disease and TSAT levels of 30–40% experienced significantly fewer cardiovascular events than those with TSAT of 20–30%.

Our June 2024 month-in-review for hematology focuses on the latest updates to the hematologic pipeline.

Nearly half of patients with CKD presented with iron deficiency at the initial presentation at the nephrology department.

Mezagitamab demonstrated no new safety signals and rapid increases in platelet counts across Phase 2b data in treating persistent or chronic ITP.

Exposure to carbon monoxide correlated with lower odds of anemia prevalence, whereas exposure to fine particulate matter had the opposite effect.

Early detection from a universal newborn screening program in Canada significantly reduced disease-related burden in children with SCD.

Genetically predicted anemia may be casually linked to an increased risk of asthma, suggesting its role in the chronic lung disease's development.

Late-breaking data from EHA 2024 demonstrated a high overall response rate and favorable safety across a range of sHLH patients treated with ELA026.

Bitopertin achieves significant reductions in PPIX versus placebo in patients with erythropoietic protoporphyria.

Long-term Phase 2 data demonstrate KP104's potential as an optimal first-line monotherapy for PNH.

In the ENERGIZE trial, oral mitapivat achieved meaningful improvements in symptoms of anemia in patients with non-transfusion-dependent thalassemia.